Primary androgen deprivation therapy in men with prostate cancer

JAMA

Volumn 301, Issue 1, 2009, Pages 35-

  Laufman, Leslie ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN DEPRIVATION THERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CONSERVATIVE TREATMENT; HUMAN; LETTER; MALE; OVERALL SURVIVAL; POOR GENERAL CONDITION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; MORTALITY; NEOPLASM; NOTE; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 58149400613     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2008.903     Document Type: Letter

References (2)

1. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300(2):173-181.
2. O'Dowd G, Veltri R, Orozco R, Miller M, Oesterling J. Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol. 1997;158(3 pt 1):687-698.